SHANGHAI, May 25, 2026 — As Shanghai accelerates its position as a global hub for science and technology, a milestone event has reshaped the international medical device landscape. The official inauguration ceremony for the Global Medical Device Training, Exhibition, Trading, and Innovation Center was successfully held today in the Shanghai Eastern Hub International Commercial Zone.
Simultaneously, the A3 International Medical Technology Innovation Exchange Center (A3 Center)—the first open medical technology innovation hub globally by Boston Scientific—announced its official launch. Guided by local authorities and co-organized by industry giants Siemens Healthineers and Danaher, this mega-hub marks a decisive shift toward localized, collaborative healthcare innovation in China.
1. Transforming the MedTech Supply Chain: From Open Platform to Innovation Ecosystem
The medical device industry thrives on high-level integration, from raw R&D to real-world clinical validation. Driven by Shanghai’s strategic development plans, the newly established center bridges the gap between global medical resources and frontline clinical applications.
Located in the highly connected Shanghai Eastern Hub, the center leverages cross-border institutional flexibility to streamline the flow of global MedTech assets.
“The unveiling of this center is a concrete execution of the Shanghai 15th Five-Year Plan,” stated Zhao Yugang, Deputy Director of the Shanghai Eastern Hub International Commercial Zone Authority. “By establishing an international medical device training and innovation platform, we are building a new benchmark for gateway openness and high-end industrial clustering.”
2. Inside the A3 Center: Driving the “A3” Advantage in Precision Medicine
As the flagship project within the innovation center, the A3 Center represents an open alliance model. Jointly operated by Boston Scientific, Siemens Healthineers, and Danaher, the platform focuses heavily on three critical therapeutic areas: cardiovascular/cerebrovascular diseases, oncology, and neuromodulation.
The “A3” designation highlights three core competencies that are set to redefine precision medicine:
- Advanced Technology: Integrating market-leading medical devices and minimally invasive therapies.
- Application-Driven Scenarios: Rooting technological iteration directly in China’s diverse and rich clinical environments.
- AI-Driven Diagnostics: Utilizing artificial intelligence to optimize early screening, rapid diagnostics, and precise treatment paths.
Beyond technology, the A3 Center features a digitalized capacity-building platform. By utilizing smart teaching systems and remote connectivity, it will share cutting-edge surgical techniques and clinical expertise with medical professionals across China and “Belt and Road” nations.
3. Industry Leaders on the Future of Global MedTech Synergy
The grand opening brought together top executives from the collaborating multinational enterprises, who shared insights into the evolving landscape of global healthcare:
Pioneering Open Innovation
Zhang Jun, President of Boston Scientific Greater China, emphasized that isolated R&D is a thing of the past:
“Medical innovation can no longer rely on a single company. AI is reshaping diagnostics, and cross-disciplinary integration is breaking traditional boundaries. We built the A3 Center to answer the call for high-quality industrial development. The future belongs to those who embrace openness and turn the ‘impossible’ into the ‘possible.'”
Reshaping the Global Healthcare Cycle
Wang Hao, President of Siemens Healthineers Greater China and Member of the Global Leadership Committee, highlighted the systemic shift in collaborative clinical validation:
“We are witnessing a paradigm leap in medical collaboration. Through the A3 Center, we expect medical innovation to originate from China’s vast clinical needs, accelerate through global validation, and ultimately benefit patients worldwide. Siemens Healthineers is committed to fueling this ‘new cycle’ of global healthcare innovation.”
Conclusion & Outlook
The launch of the Global Medical Device Innovation Center in Shanghai is more than a regional milestone—it is a compass for the future of global healthcare. By blending multinational R&D capabilities with local clinical insights, the center is uniquely positioned to fast-track the next generation of life-saving medical devices to the global market.